Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 154

Results For "Risk"

1536 News Found

Lupin launches posaconazole delayed-release tablets
News | February 18, 2021

Lupin launches posaconazole delayed-release tablets

posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.


Steady performance; for Alkem Laboratories: ICICI Securities
News | February 13, 2021

Steady performance; for Alkem Laboratories: ICICI Securities

The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21


Jubilant Pharmova recovers: ICICI Securities
News | February 13, 2021

Jubilant Pharmova recovers: ICICI Securities

Jubilant announced the completion of demerger of pharma and LSI business into two separate companies


Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities
News | January 26, 2021

Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities

Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.


Slow recovery in biosimilars for Biocon: ICICI Securities
News | January 26, 2021

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business